CRISPR Therapeutics (CRSP) Announces $325M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
CRISPR Therapeutics (CRSP) Prices 6.428M Share Common Offering at $70/Sh
July 1, 2020 5:53 AM EDTCRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day... More
Piper Sandler Reiterates Bullish View on CRISPR Therapeutics (CRSP) Amid New Manufacturing Facility
June 29, 2020 8:59 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $104.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) citing a new manufacturing facility to produce cell therapies for clinical and commercial use, the hiring of up to 100 more full-time employees, Car-T advancing, and AACR II showing superior features of Allo Car-T Pipeline.
The... More
CRISPR Therapeutics (CRSP) Announces the Build-Out of New Cell Therapy Manufacturing Facility
June 25, 2020 8:08 AM EDTCRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the Companys investigational cell therapy product... More
